One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 305-306

  Song, In Ho ^a   Heldmann, Frank ^b   Rudwaleit, Martin ^a,c   Listing, Joachim ^d   Appel, Heiner ^a   Haug Rost, Iris ^e   Braun, Jürgen ^b   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre of Rheumatology   (Germany)

^c Endokrinologikum   (Germany)

^d German Rheumatism Research Center   (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHYLPREDNISOLONE; RITUXIMAB;

ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RETREATMENT; SCORING SYSTEM; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FOLLOW-UP STUDIES; HUMANS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84872086509     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201926     Document Type: Letter

References (7)

1. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7.
2. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
3. Haibel H, Rudwaleit M, Listing J, et al . Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8.
4. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
5. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10.
6. Sieper J, Porter-Brown B, Thompson L, et al. Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2012;71(Suppl 3):110.
7. Sieper J, Inman RD, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN). Ann Rheum Dis 2012;71(Suppl 3):111.